Shangqing Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shangqing Ren has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Dong Wang
Robotic Minimally Invasive Surgery Center, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
10 shared publications Yang Zheng
Department of Robotic Minimally Invasive Surgery Center, ichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital and Affiliated Hospital of the University of Electronic Science and Technology of China, Chengdu, China
10 shared publicationsYong Ou
Department of Urology, Xichang People’s Hospital, Xichang, China
10 shared publications- Dong Wang
Robotic Minimally Invasive Surgery Center, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China
6 shared publications Ting Hu
Robotic Minimally Invasive Surgery Center, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
6 shared publicationsChengpeng Gu
Robotic Minimally Invasive Surgery Center, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
5 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1899751
Prognostic performance of preoperative systemic inflammatory biomarkers in upper tract urothelial carcinoma after radical nephroureterectomy: a systematic review and meta-analysis of NLR, MLR, PLR, SII and SIRI
Background: Risk stratification remains challenging in patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). Preoperative systemic inflammatory biomarkers may provide prognostic information, but their relative clinical utility remains unclear. Methods: This systematic review and meta-analysis evaluated five commonly used preoperative inflammatory biomarkers—neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)—in patients with UTUC treated with RNU. PubMed, Embase, Web of Science, and Cochrane Library were searched up to March 2026. Multivariate hazard ratios (HRs) for overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were pooled using random-effects models. Evidence certainty was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: Twelve retrospective studies comprising 7,346 patients were included. Elevated inflammatory biomarker levels were generally associated with worse survival outcomes across available studies. Significant associations with overall survival were observed for SIRI (pooled HR 2.09, 95% CI 1.27–3.44), NLR (pooled HR 1.97, 95% CI 1.74–2.22, I²=14.1%), MLR, SII, and PLR; comparable associations were seen for cancer-specific and recurrence-free survival. Each biomarker was analysed in a separate meta-analysis, and the contributing studies differed in design, populations, and cut-off values; the markers were therefore not compared statistically, and no inference regarding their relative prognostic performance is made. Conclusion: Preoperative systemic inflammatory biomarkers are individually associated with oncological outcomes following RNU for UTUC. Because each marker was pooled separately and the studies were clinically heterogeneous, the markers were not compared statistically and no ranking is implied; the findings are descriptive and hypothesis-generating. This meta-analysis of aggregate data did not assess predictive performance (discrimination, calibration, or clinical utility), and any SIRI–NLR combination remains a hypothesis requiring prospective, individual-patient-data validation before any clinical application. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261307425 , identifier CRD420261307425.
- 29 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1899751
Open AccessPrognostic performance of preoperative systemic inflammatory biomarkers in upper tract urothelial carcinoma after radical nephroureterectomy: a systematic review and meta-analysis of NLR, MLR, PLR, SII and SIRI
Background: Risk stratification remains challenging in patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). Preoperative systemic inflammatory biomarkers may provide prognostic information, but their relative clinical utility remains unclear. Methods: This systematic review and meta-analysis evaluated five commonly used preoperative inflammatory biomarkers—neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)—in patients with UTUC treated with RNU. PubMed, Embase, Web of Science, and Cochrane Library were searched up to March 2026. Multivariate hazard ratios (HRs) for overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were pooled using random-effects models. Evidence certainty was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: Twelve retrospective studies comprising 7,346 patients were included. Elevated inflammatory biomarker levels were generally associated with worse survival outcomes across available studies. Significant associations with overall survival were observed for SIRI (pooled HR 2.09, 95% CI 1.27–3.44), NLR (pooled HR 1.97, 95% CI 1.74–2.22, I²=14.1%), MLR, SII, and PLR; comparable associations were seen for cancer-specific and recurrence-free survival. Each biomarker was analysed in a separate meta-analysis, and the contributing studies differed in design, populations, and cut-off values; the markers were therefore not compared statistically, and no inference regarding their relative prognostic performance is made. Conclusion: Preoperative systemic inflammatory biomarkers are individually associated with oncological outcomes following RNU for UTUC. Because each marker was pooled separately and the studies were clinically heterogeneous, the markers were not compared statistically and no ranking is implied; the findings are descriptive and hypothesis-generating. This meta-analysis of aggregate data did not assess predictive performance (discrimination, calibration, or clinical utility), and any SIRI–NLR combination remains a hypothesis requiring prospective, individual-patient-data validation before any clinical application. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261307425 , identifier CRD420261307425.
- Open Access
- 18 June 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1) , 419
Correction: Analysis of preoperative nutrition, immunity and inflammation correlation index on the prognosis of upper tract urothelial carcinoma surgical patients: a retrospective single center study
- 18 June 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1) , 419
Open AccessCorrection: Analysis of preoperative nutrition, immunity and inflammation correlation index on the prognosis of upper tract urothelial carcinoma surgical patients: a retrospective single center study
- Open Access
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1649636
Primary high-grade urothelial carcinoma of the prostate combined with acinar adenocarcinoma: first rare case report and treatment experience summary
Introduction: Primary high-grade urothelial carcinoma of the prostate (PHUCP) combined with acinar adenocarcinoma is an extremely rare malignancy, with no previously reported cases worldwide. Primary urothelial carcinoma of the prostate (PUCP) accounts for only 1%-4% of all prostate malignancies, and its clinical manifestations often overlap with common prostatic diseases such as benign prostatic hyperplasia (BPH), leading to frequent misdiagnosis. This study presents the first documented case and summarizes the diagnostic and therapeutic approach. Case presentation: A 61-year-old male patient presented with lower urinary tract symptoms and was initially diagnosed with BPH, later revised to Gleason score 10 prostate adenocarcinoma at external hospitals. Following an innovative port-free single-site robot-assisted radical prostatectomy (pf-ssRARP) at our institution, immunohistochemical analysis (CK7/CK20/GATA3 positive, prostate-specific antigen (PSA) negative) confirmed the diagnosis of PHUCP combined with acinar adenocarcinoma. Postoperatively, a surgery combined with targeted and immunotherapy regimen was initiated: leuprorelin + rezvilutamide for the acinar adenocarcinoma and disitamab vedotin + toripalimab for the urothelial carcinoma. No recurrence or metastasis was observed during the 1-year follow-up period. Conclusion: This case underscores the diagnostic challenges of prostatic urothelial carcinoma and highlights the importance of immunohistochemistry in cases with normal PSA but rapid progression. The protocol of surgery combined with targeted and immunotherapy offers a new treatment strategy for this rare malignancy. This study provides valuable insights for clinical diagnosis and management.
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1649636
Open AccessPrimary high-grade urothelial carcinoma of the prostate combined with acinar adenocarcinoma: first rare case report and treatment experience summary
Introduction: Primary high-grade urothelial carcinoma of the prostate (PHUCP) combined with acinar adenocarcinoma is an extremely rare malignancy, with no previously reported cases worldwide. Primary urothelial carcinoma of the prostate (PUCP) accounts for only 1%-4% of all prostate malignancies, and its clinical manifestations often overlap with common prostatic diseases such as benign prostatic hyperplasia (BPH), leading to frequent misdiagnosis. This study presents the first documented case and summarizes the diagnostic and therapeutic approach. Case presentation: A 61-year-old male patient presented with lower urinary tract symptoms and was initially diagnosed with BPH, later revised to Gleason score 10 prostate adenocarcinoma at external hospitals. Following an innovative port-free single-site robot-assisted radical prostatectomy (pf-ssRARP) at our institution, immunohistochemical analysis (CK7/CK20/GATA3 positive, prostate-specific antigen (PSA) negative) confirmed the diagnosis of PHUCP combined with acinar adenocarcinoma. Postoperatively, a surgery combined with targeted and immunotherapy regimen was initiated: leuprorelin + rezvilutamide for the acinar adenocarcinoma and disitamab vedotin + toripalimab for the urothelial carcinoma. No recurrence or metastasis was observed during the 1-year follow-up period. Conclusion: This case underscores the diagnostic challenges of prostatic urothelial carcinoma and highlights the importance of immunohistochemistry in cases with normal PSA but rapid progression. The protocol of surgery combined with targeted and immunotherapy offers a new treatment strategy for this rare malignancy. This study provides valuable insights for clinical diagnosis and management.
- Open Access
- 19 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1608339
Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study
Introduction: Effective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression. Due to the lack of a head-to-head comparison of darolutamide (DARO) and abiraterone acetate plus prednisone (AAP) doublet regimen, this study aims to compare the efficacy and safety of DARO + ADT and AAP + ADT in the treatment of mHSPC in the real world.Methods: This study retrospectively analyzed patients with mHSPC who received DARO or AAP treatment in Sichuan Provincial People’s Hospital from January 2022 to June 2024, with follow-up until December 2024. The clinical data and prostate-specific antigen (PSA) changes of patients were collected. The primary endpoint was time to metastatic castration-resistant prostate cancer (mCRPC), and the secondary endpoints were overall survival (OS), radiological progression-free survival (rPFS), time to PSA progression, time to pain progression, and time to subsequent prostate cancer therapy.Results: A total of 178 patients were included, with 96 in the DARO group and 82 in the AAP group. The baseline characteristics of the two groups were comparable. The median follow-up time and interquartile ranges of the DARO and AAP groups were 12.0 [7.9–17.6] months and 17.4 [9.3–23.8] months, respectively. For the primary endpoint, DARO significantly delayed the time to mCRPC versus AAP [HR, 0.41 (95%CI, 0.23 to 0.71); P < 0.005]. And the DARO group significantly benefited in all secondary endpoints. DARO significantly led to deeper PSA reduction compared to AAP, with higher median reduction rates, better PSA50 and PSA90 remission rates, and a higher proportion of patients reaching lower PSA values. The incidence of adverse reactions was similar in the two groups, and there was no grade 3 or above drug-related adverse reactions.Conclusion: In the treatment of mHSPC, DARO + ADT was associated with significant improvement of clinical outcomes versus AAP + ADT, while their safety is comparable.
- 19 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1608339
Open AccessEfficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study
Introduction: Effective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression. Due to the lack of a head-to-head comparison of darolutamide (DARO) and abiraterone acetate plus prednisone (AAP) doublet regimen, this study aims to compare the efficacy and safety of DARO + ADT and AAP + ADT in the treatment of mHSPC in the real world.Methods: This study retrospectively analyzed patients with mHSPC who received DARO or AAP treatment in Sichuan Provincial People’s Hospital from January 2022 to June 2024, with follow-up until December 2024. The clinical data and prostate-specific antigen (PSA) changes of patients were collected. The primary endpoint was time to metastatic castration-resistant prostate cancer (mCRPC), and the secondary endpoints were overall survival (OS), radiological progression-free survival (rPFS), time to PSA progression, time to pain progression, and time to subsequent prostate cancer therapy.Results: A total of 178 patients were included, with 96 in the DARO group and 82 in the AAP group. The baseline characteristics of the two groups were comparable. The median follow-up time and interquartile ranges of the DARO and AAP groups were 12.0 [7.9–17.6] months and 17.4 [9.3–23.8] months, respectively. For the primary endpoint, DARO significantly delayed the time to mCRPC versus AAP [HR, 0.41 (95%CI, 0.23 to 0.71); P < 0.005]. And the DARO group significantly benefited in all secondary endpoints. DARO significantly led to deeper PSA reduction compared to AAP, with higher median reduction rates, better PSA50 and PSA90 remission rates, and a higher proportion of patients reaching lower PSA values. The incidence of adverse reactions was similar in the two groups, and there was no grade 3 or above drug-related adverse reactions.Conclusion: In the treatment of mHSPC, DARO + ADT was associated with significant improvement of clinical outcomes versus AAP + ADT, while their safety is comparable.
- 22 March 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (22) , 1761-1776
LRRK2 reduces the sensitivity to TKI and PD-1 blockade in ccRCC via activating LPCAT1
Tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) combination therapy is emerging as a major therapeutic strategy for advanced clear cell renal cell carcinoma (ccRCC). To define the druggable targets for improvement of TKI and ICI combination therapy in ccRCC, we analyzed a commercial protein kinase inhibitor dataset and a public ccRCC dataset and identified LRRK2 as a potential candidate that can be targeted by a small molecule inhibitor. We demonstrated that LRRK2 was transcriptionally upregulated by HIF2A and enabled to drive proliferation of ccRCC cells in a manner independent of its kinase activity. LRRK2 inhibits the RBX1-mediated degradation of lipid metabolism modulator LPCAT1 to reducing the sensitivity to TKI and PD-1 blockade in ccRCC. Specifically, LRRK2/LPCAT1 upregulated IL-1β expression levels through AKT and also increased IL-1β shearing by activating inflammasome. To target the kinase-independent activity of LRRK2, we developed an LR-protac and showed that LR-protac decreased LRRK2 protein level and enhanced the antitumor effect of PD-1 blockade and TKI in ccRCC. These data indicate that LRRK2 is a viable target for improvement of the efficacy of PD-1 blockade and TKI in ccRCC.
- 22 March 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (22) , 1761-1776
LRRK2 reduces the sensitivity to TKI and PD-1 blockade in ccRCC via activating LPCAT1
Tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) combination therapy is emerging as a major therapeutic strategy for advanced clear cell renal cell carcinoma (ccRCC). To define the druggable targets for improvement of TKI and ICI combination therapy in ccRCC, we analyzed a commercial protein kinase inhibitor dataset and a public ccRCC dataset and identified LRRK2 as a potential candidate that can be targeted by a small molecule inhibitor. We demonstrated that LRRK2 was transcriptionally upregulated by HIF2A and enabled to drive proliferation of ccRCC cells in a manner independent of its kinase activity. LRRK2 inhibits the RBX1-mediated degradation of lipid metabolism modulator LPCAT1 to reducing the sensitivity to TKI and PD-1 blockade in ccRCC. Specifically, LRRK2/LPCAT1 upregulated IL-1β expression levels through AKT and also increased IL-1β shearing by activating inflammasome. To target the kinase-independent activity of LRRK2, we developed an LR-protac and showed that LR-protac decreased LRRK2 protein level and enhanced the antitumor effect of PD-1 blockade and TKI in ccRCC. These data indicate that LRRK2 is a viable target for improvement of the efficacy of PD-1 blockade and TKI in ccRCC.
- 24 February 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (6) , 1415-1431
Causes of death in patients with malignant adrenal tumours: a population-based analysis
Objective This study aimed to characterize the causes of death and compute the risk of mortality due to each cause among patients with malignant adrenal tumours. Methods Data from malignant adrenal tumour patients were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2020). With reference data from the general population, the standardized mortality ratio (SMR) was calculated to assess all causes of death for malignant adrenal tumour patients. Results A total of 1651 patients who died from primary malignant adrenal neoplasms were included; 854 cases of adrenocortical carcinoma (ACC)-related death, 118 cases of pheochromocytoma (PCC)-related death and 333 cases of neuroblastoma (NB)-related death were identified for further analysis. Approximately 56.78%~87.69% of patients died from primary malignant adrenal tumours, 7.21%~13.56% died from secondary malignant neoplasms (SMNs), and 5.11%~29.66% died from noncancer diseases. The main causes of death associated with SMNs included lung and bronchial cancer and soft tissue cancers, including heart, kidney and renal pelvis cancers; the noncancer causes of death included mainly heart disease, septicemia, and cerebrovascular disease. Compared with chemotherapy-naïve patients, chemotherapy-treated patients had higher SMRs of SMNs, including cancers of the colon (excluding the rectum), lung, bronchus, bones and joints; soft tissues, including the heart, kidney and renal pelvis; the brain and peripheral nervous system; and leukaemia, as well as nontumor diseases, including heart disease, septicemia, and cerebrovascular disease. Patients with NB were more likely to die from SMNs, including soft-tissue malignancies of the heart, bones and joints; brain; peripheral nervous system; the female genital system, including the ovary; leukaemia, including lymphocytic leukaemia; myeloid and monocytic leukaemia; and lymphoma, including non-Hodgkin lymphoma. Conclusion In addition to primary cancer, SMNs and nontumor diseases were important causes of death in patients with malignant adrenal tumours. Neuroblastoma patients and chemotherapy- treated patients are more likely to die from SMNs and should monitored closely.
- 24 February 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (6) , 1415-1431
Causes of death in patients with malignant adrenal tumours: a population-based analysis
Objective This study aimed to characterize the causes of death and compute the risk of mortality due to each cause among patients with malignant adrenal tumours. Methods Data from malignant adrenal tumour patients were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2020). With reference data from the general population, the standardized mortality ratio (SMR) was calculated to assess all causes of death for malignant adrenal tumour patients. Results A total of 1651 patients who died from primary malignant adrenal neoplasms were included; 854 cases of adrenocortical carcinoma (ACC)-related death, 118 cases of pheochromocytoma (PCC)-related death and 333 cases of neuroblastoma (NB)-related death were identified for further analysis. Approximately 56.78%~87.69% of patients died from primary malignant adrenal tumours, 7.21%~13.56% died from secondary malignant neoplasms (SMNs), and 5.11%~29.66% died from noncancer diseases. The main causes of death associated with SMNs included lung and bronchial cancer and soft tissue cancers, including heart, kidney and renal pelvis cancers; the noncancer causes of death included mainly heart disease, septicemia, and cerebrovascular disease. Compared with chemotherapy-naïve patients, chemotherapy-treated patients had higher SMRs of SMNs, including cancers of the colon (excluding the rectum), lung, bronchus, bones and joints; soft tissues, including the heart, kidney and renal pelvis; the brain and peripheral nervous system; and leukaemia, as well as nontumor diseases, including heart disease, septicemia, and cerebrovascular disease. Patients with NB were more likely to die from SMNs, including soft-tissue malignancies of the heart, bones and joints; brain; peripheral nervous system; the female genital system, including the ovary; leukaemia, including lymphocytic leukaemia; myeloid and monocytic leukaemia; and lymphoma, including non-Hodgkin lymphoma. Conclusion In addition to primary cancer, SMNs and nontumor diseases were important causes of death in patients with malignant adrenal tumours. Neuroblastoma patients and chemotherapy- treated patients are more likely to die from SMNs and should monitored closely.
- Open Access
- 11 November 2024
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 18 (1) , 1
Correction: Experience with an innovative surgical approach: 321 cases modified extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy without dedicated PORT based on Da Vinci SI system
- 11 November 2024
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 18 (1) , 1
Open AccessCorrection: Experience with an innovative surgical approach: 321 cases modified extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy without dedicated PORT based on Da Vinci SI system
- 23 October 2024
- Published by Springer Nature in Oncogene
- Vol. 43 (50) , 3633-3644
PTPRZ1 dephosphorylates and stabilizes RNF26 to reduce the efficacy of TKIs and PD-1 blockade in ccRCC
Clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma, often exhibits resistance to tyrosine kinase inhibitors (TKIs) when used as monotherapy. However, the integration of PD-1 blockade with TKIs has significantly improved patient survival, making it a leading therapeutic strategy for ccRCC. Despite these advancements, the efficacy of this combined therapy remains suboptimal, necessitating a deeper understanding of the underlying regulatory mechanisms. Through comprehensive analyses, including mass spectrometry, RNA sequencing, lipidomic profiling, immunohistochemical staining, and ex vivo experiments, we explored the interaction between PTPRZ1 and RNF26 and its impact on ccRCC cell behavior. Our results revealed a unique interaction where PTPRZ1 stabilized RNF26 protein expression by dephosphorylating it at the Y432 site. The modulation of RNF26 levels by PTPRZ1 was found to be mediated through the proteasome pathway. Additionally, PTPRZ1, via its interaction with RNF26, activated the TNF/NF-κB signaling pathway, thereby promoting cell proliferation, angiogenesis, and lipid metabolism in ccRCC cells. Importantly, inhibiting PTPRZ1 enhanced the sensitivity of ccRCC to TKIs and PD-1 blockade, an effect that was attenuated when RNF26 was simultaneously knocked down. These findings highlight the critical role of the PTPRZ1-RNF26 axis in ccRCC and suggest that combining PTPRZ1 inhibitors with current TKIs and PD-1 blockade therapies could significantly improve treatment outcomes for ccRCC patients.
- 23 October 2024
- Published by Springer Nature in Oncogene
- Vol. 43 (50) , 3633-3644
PTPRZ1 dephosphorylates and stabilizes RNF26 to reduce the efficacy of TKIs and PD-1 blockade in ccRCC
Clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma, often exhibits resistance to tyrosine kinase inhibitors (TKIs) when used as monotherapy. However, the integration of PD-1 blockade with TKIs has significantly improved patient survival, making it a leading therapeutic strategy for ccRCC. Despite these advancements, the efficacy of this combined therapy remains suboptimal, necessitating a deeper understanding of the underlying regulatory mechanisms. Through comprehensive analyses, including mass spectrometry, RNA sequencing, lipidomic profiling, immunohistochemical staining, and ex vivo experiments, we explored the interaction between PTPRZ1 and RNF26 and its impact on ccRCC cell behavior. Our results revealed a unique interaction where PTPRZ1 stabilized RNF26 protein expression by dephosphorylating it at the Y432 site. The modulation of RNF26 levels by PTPRZ1 was found to be mediated through the proteasome pathway. Additionally, PTPRZ1, via its interaction with RNF26, activated the TNF/NF-κB signaling pathway, thereby promoting cell proliferation, angiogenesis, and lipid metabolism in ccRCC cells. Importantly, inhibiting PTPRZ1 enhanced the sensitivity of ccRCC to TKIs and PD-1 blockade, an effect that was attenuated when RNF26 was simultaneously knocked down. These findings highlight the critical role of the PTPRZ1-RNF26 axis in ccRCC and suggest that combining PTPRZ1 inhibitors with current TKIs and PD-1 blockade therapies could significantly improve treatment outcomes for ccRCC patients.